跳至主要内容
临床试验/NL-OMON44254
NL-OMON44254招募中不适用

on-invasive assessment of lung remodeling in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) using [11C]-Nintedanib or [18F]-FLT PET imaging. - Imaging the primary disease process in IPF and PAH

Vrije Universiteit0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • 1. Diagnosis of IPF, according to ATS/ERS guidelines (ref Raghu AJRCCM 2011)
  • Diagnosis of PAH, according to ESC/ERS guidelines (ref: Galie ERJ 2015)
  • Unaffected BMPR2 mutation carrier
  • Normal control subjects
  • 2. Age >18 and <80 years

排除标准

  • - Claustrophobia
  • - Inability to provide informed consent
  • - In case of IPF patients: pulmonary hypertension suspected by echocardiography or proven by right heart
  • catheterization
  • - In case of PAH patients: TLC < 70%pred or radiographic evidence of interstitial lung disease
  • - In case of BMPR2 mutation carriers and normal control subjects, one or more of the following: abnormal
  • spirometry, TLC < 70%, echocardiographic evidence of pulmonary hypertension

研究者

相似试验

on-invasive assessment of lung remodeling in... | 临床试验